New Promising Avenue of Research for KRAS Mutation-Positive

[NikoleV]

New Promising Avenue of Research for KRAS Mutation-Positive Patients with Advanced NSCLC

February 13th, 2013 - by Dr. Jack West

http://expertblog.lungevity.org/2013/02 ... ced-nsclc/

I just recorded a brief video highlighting a publication just published in Lancet Oncology that reports results from an international, multicenter randomized phase II study led by Dr. Pasi Janne of Dana Farber Cancer Institute in Boston.

(Click link above for video)

Some prior posts have touched on this study before, as an ASCO highlight from 2012, for instance, but the publication is a major milestone. Importantly, KRAS mutations are actually the most common molecular defect we see in NSCLC, but we haven’t had an actual treatment to offer such patients up to this point.

I would say that this research suggests that we could have some particularly effective treatment options to offer to KRAS mutation-positive patients in the future.